MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

About this update from Mbx Biosciences, Inc.

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the Company's new Chief Financial Officer. All leadership changes are effective immediately. "On behalf of the entire Board, I want to thank Kent for his leadership and contributions to MBX," said Mr. Hoerter. "As a co-founder, Kent was instrumental in the company's evolution from inception to a pre-commercial organization with a robust pipeline of precision peptide therapies. His many accomplishments over the last six years include leading a successful IPO, creating significant shareholder value and building a talented team dedicated to developing these novel therapies." "As we enter our next phase of growth, we remain committed to our mission of improving the lives of patients living with endocrine and metabolic diseases," Mr. Hoerter continued. "I am honored to lead the Company during this important period, and I look forward to working with our Board and the exceptional MBX team to provide the experience, continuity and strategic leadership needed to execute on our long-term strategy. We remain on track to deliver on our three key milestones in the second half of 2026: initiation of the Phase 3 trial of canvuparatide in chronic hypoparathyroidism, nomination of a GLP-1/GIP/GCGR triple agonist candidate for obesity and the highly anticipated 12-week multiple ascending dose data from MBX 4291."  Mr. Hoerter joined the MBX Board of Directors in April 2025 and was appointed Executive Chairman in November 2025. He brings a track record of building and scaling successful commercial-stage biotechnology companies. Most recently, Mr. Hoerter served as President and Chief Executive Officer of Deciphera Pharmaceuticals, where he led the company's transformation from a research and development organization to a successful commercial-stage company in the United States and Europe until its acquisition by Ono Pharmaceutical in 2024.

View stock analysis, news, and events for Mbx Biosciences, Inc.